A Study of the Safety, Tolerability, and Drug/Body Interactions of C2N-8E12 in People with Progressive Supranuclear Palsy

Overview

About this study

The purpose of this study is to evaluate the safety, tolerability and drug/body interactions of C2N-8E12 in patients with progressive supranuclear palsy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria 

  • Meets NINDS-SPSP possible or probable criteria as modified for NNIPPS and AL-108-231 clinical trials
  • Brain MRI at screening is consistent with Progressive Supranuclear Palsy
  • Stable medications for Parkinsonism for at least 2 months prior to screening
  • Agree to use protocol specified methods of contraception

Exclusion Criteria

  • Signs of a progressive neurological disorder that better meets the criteria for types of neurological disorders other than PSP
  • Currently on any other biologic or immunomodulatory therapy
  • Subjects that reside at a skilled nursing or dementia care facility
  • Diagnosis of any other significant unrelated neurological or psychiatric disorders that could account for cognitive deficits
  • Untreated major depression at baseline evaluation, based on clinical judgment and results in geriatric depression scale
  • Unable to tolerate MRI scan at screening or any other contraindication to MRI
  • Any contraindication to or unable to tolerate lumbar puncture at screening, including use of anti-coagulant medications

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20198649

Mayo Clinic Footer